Patricia K. Coyle, MD

Articles

Ofatumumab and the Anti-CD20 Class

October 26, 2021

An expert discusses takeaways about the anti-CD20 monoclonal antibody class of disease-modifying therapies for patients with relapsing multiple sclerosis through the lens of ofatumumab (Kesimpta; Novartis).

Managing Multiple Sclerosis in the Community Setting

June 21, 2021

Advice to community physicians and neurologists who play a role in caring for patients with multiple sclerosis in community practices on optimizing therapy with high-efficacy and newer treatment options.